University Hospital St Luc, Brussels
13
3
3
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.7%
1 terminated/withdrawn out of 13 trials
88.9%
+2.4% vs industry average
15%
2 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Providing Standardized Consented PROMs (Patient Reported Outcome Measures) for Improving Pain Treatment
Role: collaborator
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
Role: collaborator
OCT Guided Magmaris RMS in STEMI
Role: collaborator
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Role: collaborator
Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan
Role: collaborator
Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study
Role: collaborator
The Effect of 3 Ropivacaine Suprascapular Nerve Blocks in Subacute Adhesive Capsulitis: a Randomized Controlled Trial
Role: collaborator
Pulmonary Function Test Study - Automated Interpretation
Role: collaborator
N-Acetylcysteine in Patients With Sickle Cell Disease
Role: collaborator
Pharmacokinetics of Nebulized Amikacin in Non Invasive Ventilated Healthy Volunteers.
Role: lead
In Vitro Assessment of a Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation
Role: lead
Long Term Significance (Survival) of LCI in Patients With Cystic Fibrosis
Role: lead
Neurally Adjusted Ventilatory Assist for Non Invasive Ventilation and Patient-ventilator Interaction
Role: collaborator
All 13 trials loaded